flexipharm austrading limited
flexipharm austrading limited Company Information
Company Number
11368401
Website
-Registered Address
a t i house 6 boston drive, bourne end, buckinghamshire, SL8 5YS
Industry
Agents specialised in the sale of other particular products
Telephone
01480273425
Next Accounts Due
September 2025
Group Structure
View All
Shareholders
michael leslie clark 60%
phebra holdings pty limited 40%
flexipharm austrading limited Estimated Valuation
Pomanda estimates the enterprise value of FLEXIPHARM AUSTRADING LIMITED at £3.6m based on a Turnover of £5.8m and 0.62x industry multiple (adjusted for size and gross margin).
flexipharm austrading limited Estimated Valuation
Pomanda estimates the enterprise value of FLEXIPHARM AUSTRADING LIMITED at £30.8k based on an EBITDA of £6.9k and a 4.49x industry multiple (adjusted for size and gross margin).
flexipharm austrading limited Estimated Valuation
Pomanda estimates the enterprise value of FLEXIPHARM AUSTRADING LIMITED at £1.2m based on Net Assets of £928.6k and 1.28x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Flexipharm Austrading Limited AI Business Plan
In just minutes, we combine Pomanda’s company and industry data with cutting edge Artificial Intelligence to build a comprehensive 27 section business plan. You then have 60 days to tailor the information, decide which sections to include or exclude, and add your own branding logos, images and color scheme to create your perfect plan.
Flexipharm Austrading Limited Overview
Flexipharm Austrading Limited is a live company located in buckinghamshire, SL8 5YS with a Companies House number of 11368401. It operates in the agents specialized in the sale of other particular products sector, SIC Code 46180. Founded in May 2018, it's largest shareholder is michael leslie clark with a 60% stake. Flexipharm Austrading Limited is a young, mid sized company, Pomanda has estimated its turnover at £5.8m with high growth in recent years.
Upgrade for unlimited company reports & a free credit check
Flexipharm Austrading Limited Health Check
Pomanda's financial health check has awarded Flexipharm Austrading Limited a 4 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 5 areas for improvement. Company Health Check FAQs
4 Strong
3 Regular
5 Weak
Size
annual sales of £5.8m, make it smaller than the average company (£10.1m)
- Flexipharm Austrading Limited
£10.1m - Industry AVG
Growth
3 year (CAGR) sales growth of 18%, show it is growing at a faster rate (7.9%)
- Flexipharm Austrading Limited
7.9% - Industry AVG
Production
with a gross margin of 28%, this company has a comparable cost of product (28%)
- Flexipharm Austrading Limited
28% - Industry AVG
Profitability
an operating margin of 0% make it less profitable than the average company (5.7%)
- Flexipharm Austrading Limited
5.7% - Industry AVG
Employees
with 1 employees, this is below the industry average (15)
1 - Flexipharm Austrading Limited
15 - Industry AVG
Pay Structure
on an average salary of £59.1k, the company has an equivalent pay structure (£59.1k)
- Flexipharm Austrading Limited
£59.1k - Industry AVG
Efficiency
resulting in sales per employee of £5.8m, this is more efficient (£389.2k)
- Flexipharm Austrading Limited
£389.2k - Industry AVG
Debtor Days
it gets paid by customers after 45 days, this is near the average (52 days)
- Flexipharm Austrading Limited
52 days - Industry AVG
Creditor Days
its suppliers are paid after 120 days, this is slower than average (29 days)
- Flexipharm Austrading Limited
29 days - Industry AVG
Stock Days
it holds stock equivalent to 105 days, this is more than average (65 days)
- Flexipharm Austrading Limited
65 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 23 weeks, this is more cash available to meet short term requirements (18 weeks)
23 weeks - Flexipharm Austrading Limited
18 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 66.4%, this is a higher level of debt than the average (54.7%)
66.4% - Flexipharm Austrading Limited
54.7% - Industry AVG
flexipharm austrading limited Credit Report and Business Information
Flexipharm Austrading Limited Competitor Analysis
Perform a competitor analysis for flexipharm austrading limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
flexipharm austrading limited Ownership
FLEXIPHARM AUSTRADING LIMITED group structure
Flexipharm Austrading Limited has no subsidiary companies.
Ultimate parent company
FLEXIPHARM AUSTRADING LIMITED
11368401
flexipharm austrading limited directors
Flexipharm Austrading Limited currently has 3 directors. The longest serving directors include Mr Michael Clark (May 2018) and Mr Michael Clark (May 2018).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Michael Clark | England | 60 years | May 2018 | - | Director |
| Mr Michael Clark | England | 60 years | May 2018 | - | Director |
| Mr Andre Vlok | England | 64 years | Nov 2021 | - | Director |
FLEXIPHARM AUSTRADING LIMITED financials
Flexipharm Austrading Limited's latest turnover from December 2023 is estimated at £5.8 million and the company has net assets of £928.6 thousand. According to their latest financial statements, Flexipharm Austrading Limited has 1 employee and maintains cash reserves of £819.5 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | |
|---|---|---|---|---|---|---|
| Turnover | 3,489,565 | 0 | ||||
| Other Income Or Grants | 0 | 0 | ||||
| Cost Of Sales | 2,553,419 | 47,392 | ||||
| Gross Profit | 745,495 | 1,030,761 | 936,146 | 441,976 | -47,392 | |
| Admin Expenses | 357,790 | 264,769 | 176,163 | 143,294 | 70,533 | |
| Operating Profit | 387,705 | 765,992 | 759,983 | 298,682 | -117,925 | |
| Interest Payable | 1,027 | 1,799 | 510 | 0 | 0 | |
| Interest Receivable | 0 | 0 | 1,911 | 0 | 0 | |
| Pre-Tax Profit | 386,678 | 764,193 | 761,384 | 298,682 | -117,925 | |
| Tax | -74,069 | -154,960 | 0 | -57,568 | 21,286 | |
| Profit After Tax | 312,609 | 609,233 | 761,384 | 241,114 | -96,639 | |
| Dividends Paid | 0 | 782,038 | 0 | 0 | 0 | |
| Retained Profit | 312,609 | -172,805 | 761,384 | 241,114 | -96,639 | |
| Employee Costs | 204,503 | 105,504 | 8,745 | 3,595 | 0 | |
| Number Of Employees | 1 | 1 | 1 | 1 | ||
| EBITDA* | 393,128 | 769,420 | 763,515 | 306,516 | -117,863 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | |
|---|---|---|---|---|---|---|
| Tangible Assets | 8,312 | 4,570 | 6,699 | 2,834 | 4,022 | 670 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 8,312 | 4,570 | 6,699 | 2,834 | 4,022 | 670 |
| Stock & work in progress | 1,198,302 | 996,299 | 259,465 | 547,702 | 718,458 | 0 |
| Trade Debtors | 722,545 | 346,746 | 49,798 | 234,941 | 271,335 | 36,232 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 12,134 | 0 | 0 | 0 | 0 | 0 |
| Cash | 819,543 | 671,294 | 727,738 | 1,511,235 | 777,563 | 17,985 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 2,752,524 | 2,014,339 | 1,037,001 | 2,293,878 | 1,767,356 | 54,217 |
| total assets | 2,760,836 | 2,018,909 | 1,043,700 | 2,296,712 | 1,771,378 | 54,887 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 1,373,266 | 1,119,252 | 456,654 | 1,373,243 | 1,506,803 | 91,426 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 459,004 | 0 | 0 | 0 | 0 | 0 |
| total current liabilities | 1,832,270 | 1,119,252 | 456,654 | 1,373,243 | 1,506,803 | 91,426 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 163,616 | 120,000 | 60,000 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 163,616 | 120,000 | 60,000 |
| total liabilities | 1,832,270 | 1,119,252 | 456,654 | 1,536,859 | 1,626,803 | 151,426 |
| net assets | 928,566 | 899,657 | 587,046 | 759,853 | 144,575 | -96,539 |
| total shareholders funds | 928,566 | 899,657 | 587,046 | 759,853 | 144,575 | -96,539 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Operating Profit | 387,705 | 765,992 | 759,983 | 298,682 | -117,925 | |
| Depreciation | 5,579 | 5,423 | 3,428 | 3,532 | 1,934 | 62 |
| Amortisation | 0 | 0 | 0 | 0 | 5,900 | 0 |
| Tax | -74,069 | -154,960 | 0 | -57,568 | 21,286 | |
| Stock | 202,003 | 736,834 | -288,237 | -170,756 | 718,458 | 0 |
| Debtors | 387,933 | 296,948 | -185,143 | -36,394 | 235,103 | 36,232 |
| Creditors | 254,014 | 662,598 | -916,589 | -133,560 | 1,415,377 | 91,426 |
| Accruals and Deferred Income | 459,004 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | -52,125 | 171,251 | 837,105 | 710,764 | -41,383 | |
| Investing Activities | ||||||
| capital expenditure | ||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||
| Financing Activities | ||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | -163,616 | 43,616 | 60,000 | 60,000 |
| share issue | ||||||
| interest | -1,027 | -1,799 | 1,401 | 0 | 0 | |
| cash flow from financing | -1,025 | -165,417 | -101,089 | 60,000 | 60,100 | |
| cash and cash equivalents | ||||||
| cash | 148,249 | -56,444 | -783,497 | 733,672 | 759,578 | 17,985 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 148,249 | -56,444 | -783,497 | 733,672 | 759,578 | 17,985 |
P&L
December 2023turnover
5.8m
+57%
operating profit
1.3k
0%
gross margin
28.1%
+37.95%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
928.6k
+0.03%
total assets
2.8m
+0.37%
cash
819.5k
+0.22%
net assets
Total assets minus all liabilities
Similar Companies
flexipharm austrading limited company details
company number
11368401
Type
Private limited with Share Capital
industry
46180 - Agents specialised in the sale of other particular products
incorporation date
May 2018
age
6
accounts
Total Exemption Full
ultimate parent company
previous names
N/A
incorporated
UK
address
a t i house 6 boston drive, bourne end, buckinghamshire, SL8 5YS
last accounts submitted
December 2023
flexipharm austrading limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to flexipharm austrading limited.
flexipharm austrading limited Companies House Filings - See Documents
| date | description | view/download |
|---|
